Athira Pharma Inc.

03/09/2024 | Press release | Distributed by Public on 03/09/2024 20:03

Athira Pharma Announces Topline Results from Phase 2/3 LIFT AD Clinical Trial of Fosgonimeton for Mild to Moderate Alzheimer’s Disease